Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + cisplatin + irinotecan
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Paclitaxel + cisplatin + irinotecan is a combination chemotherapy regimen investigated by Memorial Sloan Kettering Cancer Center (MSKCC) for the treatment of advanced solid tumors, with a particular focus on gastrointestinal malignancies such as gastric and esophageal adenocarcinoma. The regimen combines three cytotoxic agents with distinct mechanisms: paclitaxel, a taxane that stabilizes microtubules to inhibit mitosis; cisplatin, a platinum-based agent that forms DNA cross-links to induce apoptosis; and irinotecan, a topoisomerase I inhibitor that prevents DNA strand religation. A Phase I dose-escalation study was conducted to determine the maximum tolerated dose and safety profile of this triplet combination, identifying neutropenia as the primary dose-limiting toxicity.
- Other names
- Paclitaxel, Cisplatin, and Irinotecan combinationMSKCC Paclitaxel/Cisplatin/Irinotecan regimenpaclitaxel-Memorial Sloan Kettering Cancer Center-solid tumor
02
Targets
TUBB (Tubulin (alpha and beta subunits))TOP1 (DNA Topoisomerase I)DNA
Beyond the preview
Go deeper on paclitaxel + cisplatin + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + cisplatin + irinotecan.